|Bid||42.46 x 60000|
|Ask||43.05 x 60000|
|Day's Range||42.50 - 43.01|
|52 Week Range||23.88 - 43.01|
|Beta (3Y Monthly)||0.60|
|PE Ratio (TTM)||36.79|
|Forward Dividend & Yield||0.14 (0.33%)|
|1y Target Est||N/A|
Bruker (BRKR) delivered earnings and revenue surprises of 23.33% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.